Source: Business Wire via Yahoo! Finance
Posted: May 8, 2006
Studies Continue to Evaluate Clinical and Therapeutic Potential of Rare Cord Blood Stem Cell to Treat Respiratory Conditions
Summary:
ST. PAUL, Minn.--(BioE(R), Inc., a biotechnology company that develps and supplies cellular tools for drug discovery and therapeutic research, announced it has derived its trademark Multi-Lineage Progenitor Cell(TM) (MLPC(TM)) from cord blood and differentiated it into lung cells responsible for making surfactant, a substance enabling respiration.
Researchers believe this is the first time human stem cells -- from any source -- have differentiated into type II alveolar cells, the type of epithelial cells that help stabilize the lung's air sacs during breathing.
The discovery is being hailed as a signficant breakthrough that could lead to treatments for a number of respiratory conditions -- such as emphysema and pulmonary fibrosis, as well as pulmonary injury.
Commentary: Hopefully this discovery will lead to positive treatment outcomes in human patients with respiratory conditions in the near future.
No comments:
Post a Comment